Ventilator companies scramble for other ways to utilise capacities

Doctors are now shifting treatment protocol for Covid-19 at hospitals and invasive ventilation is not being preferred

ventilator
From a mere 300 ventilators per month in March 2020, India’s ventilator making capacity touched a whopping 30,000 units by July
Vinay UmarjiSohini Das Ahmedabad/Mumbai
3 min read Last Updated : Feb 24 2021 | 6:10 AM IST
A gradual decline in critical Covid-19 cases and a shift in the treatment protocol by doctors have prompted ventilator manufacturers in the country to look for other ways to utilise their capacities. 

From a mere 300 ventilators per month in March 2020, India’s ventilator making capacity touched a whopping 30,000 units by July. 

This had led to foray into ventilator manufacturing by non-medical device players like Rajkot-based Jyoti CNC. 

It also resulted in conventional players adding capacities to meet the demand surge.

However, doctors are now shifting treatment protocol for Covid-19 at hospitals and invasive ventilation is not being preferred.

“Around 55,000 ventilators were sold during the pandemic and my estimate is that much of it is not utilised. I have been to hospitals to check the status of usage, and I feel around 20,000 units are not in use. The treatment protocol for Covid-19 has shifted and ventilators are no longer the preferred mode,” said V Alva, founder and managing director (MD), Skanray Technologies. 

As a result, ventilator manufacturers are now looking at innovative ways to utilise capacities, including repurposing them or tapping the overseas markets. 

For instance, Vadodara-based Max Ventilators has not only expanded its manufacturing capacity to 12,000 ventilators per annum but is also foraying into other medical devices to tap the export market. 

“Currently, patient monitoring systems are being imported from China and high-end ones from Europe, mainly Germany. India doesn’t have many manufacturers although it is a must in an ICU. We are gradually developing technology that is building blocks for such systems. In the next 6 months, we will hopefully have indigenous systems,” said Max Ventilators MDAshok Patel. 

Apart from expanding the conventional pneumatic-driven ventilator manufacturing capacity, the company is also looking to add turbine driven ventilators as well as hi-flow oxygen therapy devices.

The other way that Max Ventilators intends to use its capacity is through anaesthesia workstations.

Similarly, Ahmedabad-based conventional ventilator manufacturer Lifeline Biz, which is also 

witnessing a stabilisation in domestic demand, plans to add other devices to its kitty. 


“Yes, domestic demand has stabilised now. For instance, we are utilising 70 per cent of our capacity after ramping it up during peak of the pandemic last year but we are not panicking. Going forward, we will look at export as an option. We also intend to manufacture other medical devices to continue tapping the country’s market,” said Vineet Acharya, MD of Lifeline Biz.

The company is exploring manufacturing devices like anaesthesia machines and syringe infusion pump.

Jyoti CNC, on the other hand, is in the process of getting regulatory certification from the US and Europe for its ventilators that it intends to export soon. According to Alva, Skanray, the largest ventilator manufacturer, has largely remained immune to these developments.

“We had not invested to create capacity, but had made the ventilators at Bharat Electronics (BEL) facility. So, we are not worried about the lack of demand. BEL, too, had used its electronic voting machine (EVM)-making capacity to make ventilators as EVM demand is usually seasonal. Export ban has been lifted, but China has cornered most of the world market. Thus, there is not much international demand,” added Alva.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusMedical device industryIndian companiesHealth Ministry

Next Story